Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss (NCT06355856) | Clinical Trial Compass
UnknownPhase 4
Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
196 participantsStarted 2024-04
Plain-language summary
Evaluation of the efficacy and safety of DNN.22.17.036 versus 10573048700 in the treatment of male pattern hair loss.
Who can participate
Age range25 Years – 60 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF)
* Male participants age 25 or older and 60 age or younger
* Participants who have an intact scalp in the area of product analysis
* Participants with androgenetic alopecia (AGA) with AGA Norwood-Hamilton Scale \> II
* Participants with at least 20% telogen effluvium of evaluated by Tricholab
Exclusion Criteria:
* Participants who have used immunosuppressants in the 3 months prior to signing the ICF
* Participants with other causes of hair loss or scalp dermatoses
* Participants who have received hair loss treatment in the last 6 months
* Participants with uncontrolled medical conditions, kidney and liver disease
* Participants with a history of hair transplantation, malignancy, hematologic disorders, thyroid dysfunction, malnutrition, and other dermatologic disorders that contribute to hair loss
What they're measuring
1
Percentage variation of hairs in the hair loss phase